Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.

Published in: JCO precision oncology (2024)

-mutated cancers despite progression on previous platinum.

Keyphrases